biosimilars

FDA Approves Avastin Biosimilar for Six Types of Cancer
Pharmacy Times
Wed, 09/28/22 - 10:30 pm
FDA
biosimilars
Vegzelma
Avastin
non-small cell lung cancer
glioblastoma
metastatic colorectal cancer
cervical caner
metastatic renal cell carcinoma
Unsealed documents detail Biogen's fight against Sandoz Tysabri biosimilar
Endpoints
Tue, 09/20/22 - 08:36 pm
Biogen
Novartis
Sandoz
biosimilars
Tysabri
MS
multiple sclerosis
Could This Biosimilar Drug Candidate Be a Winner for Amgen?
Motley Fool
Fri, 09/9/22 - 10:57 am
Amgen
Soliris
biosimilars
ABP 959
Amgen's Neulasta gains another biosimilar competitor as sales slip
Endpoints
Thu, 09/8/22 - 04:35 pm
Amgen
Neulasta
Fresenius Kabi
biosimilars
FDA
Stimufend
Can biosimilars, after years of limited impact, finally make a mark in the US?
BioPharma Dive
Wed, 09/7/22 - 10:44 am
biosimilars
FDA holds back Alvotech’s Humira biosimilar over manufacturing issues
BioPharma Dive
Tue, 09/6/22 - 04:57 pm
Alvotech
AbbVie
Humira
biosimilars
FDA
drug manufacturing
Interchangeability without switching studies: FDA explains why a new Lucentis biosimilar may be a game-changer
Endpoints
Thu, 08/25/22 - 07:48 pm
FDA
interchangeability
biosimilars
Lucentis
Roche
Coherus Biosciences
Cimerli
Novartis tips Lucentis to weather the arrival of biosimilar copies in Europe
Biopharma Reporter
Thu, 08/11/22 - 12:30 pm
Novartis
Lucentis
biosimilars
patents
Europe
Coherus wins FDA approval for second Lucentis biosimilar, its third drug
BioPharma Dive
Wed, 08/3/22 - 09:26 pm
Coherus Biosciences
biosimilars
Lucentis
Roche
Cimerli
Biogen, watch out: Novartis' Tysabri biosim application could portend multiple sclerosis showdown in Europe and US
Fierce Pharma
Wed, 07/27/22 - 10:58 am
Novartis
Biogen
multiple sclerosis
MS
Tysabri
biosimilars
Novartis asks FDA to approve biosimilar for Biogen’s top-selling MS drug
BioPharma Dive
Mon, 07/25/22 - 09:54 pm
Novartis
FDA
Biogen
biosimilars
Tysabri
MS
multiple sclerosis
FDA reviewing higher dose Hyrimoz biosimilar
Biopharma Reporter
Fri, 07/22/22 - 11:14 am
FDA
Sandoz
biosimilars
Hyrimoz
Humira
AbbVie
Biosimilar inspections still lagging as the FDA looks to clear its backlog
Endpoints
Fri, 07/22/22 - 10:11 am
biosimilars
FDA
regulatory
regulatory inspections
Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea®
BioSpace
Thu, 07/7/22 - 10:41 am
Alvotech
AVT06
biosimilars
clinical trials
Eylea
As biosimilars gain steam, Amgen exec lays out its Humira copycat plans
Fierce Pharma
Wed, 06/22/22 - 06:57 pm
Amgen
Humira
biosimilars
More drug, fewer jabs: Novartis' Sandoz eyes EMA nod for high-concentration Humira copy
Fierce Pharma
Mon, 06/20/22 - 10:37 am
Novartis
Sandoz
AbbVie
Humira
Europe
biosimilars
autoimmune disease
EMA
Hyrimoz
Novartis’ Sandoz Launches Biosimilars Awareness Campaign to Improve Biosimilars Adoption Worldwide
Xtalks
Wed, 06/8/22 - 11:04 pm
Novartis
Sandoz
biosimilars
generics
Biogen, Samsung Bioepis launch ranibizumab-nuna in US
Ophthalmology Today
Fri, 06/3/22 - 09:11 am
Biogen
Samsung Bioepis
ranibizumab
ranibizumab-nuna
biosimilars
Roche
Lucentis
retinal disease
Novartis' Sandoz founds new initiative to expand biosimilar use more globally
Endpoints
Tue, 05/31/22 - 11:51 pm
Novartis
Sandoz
biosimilars
Microcap's effort to take on Eylea with Avastin biosimilar faces significant FDA roadblock
Endpoints
Tue, 05/31/22 - 10:51 am
Outlook Therapeutics
Avastin
biosimilars
wet age-related macular degeneration
Roche
bevacizumab

Pages